Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1Cytopenia 1Bone Marrow Failure Disorders 1Anemia, Aplastic 1

Interventions

Rituximab 259Cyclophosphamide 238Etoposide 114Prednisone 97Vincristine 96Doxorubicin 96Peripheral Blood Stem Cell Transplantation 95fludarabine phosphate 87Filgrastim 80Cytarabine 61Lenalidomide 60Mycophenolic Acid 59Melphalan 59Radiotherapy 58Busulfan 52Cyclosporine 50Carmustine 49Whole-Body Irradiation 48Tacrolimus 46Methotrexate 42Antilymphocyte Serum 38Gemcitabine 33Ifosfamide 32Carboplatin 32fludarabine 31Dexamethasone 31polatuzumab vedotin 29Granulocyte Colony-Stimulating Factor 29CT-P10 28Methylprednisolone 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Large B-Cell, Diffuse × Emapalumab × Clear all
NCT06550141 2025-11-14

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Massachusetts General Hospital

Phase 2 Recruiting
28 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡